Leukemia Clinical Trials in New York

Showing 441-460 of 1,357 trials

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

NCT02375880

DKN-01 is a humanized monoclonal antibody (Mab) with neutralizing activity against Dkk-1 and is being developed as an anti-neoplastic agent. This study is designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of DKN-01 in combination with gemcitabine and cisplatin in patients with carcinoma primary to the intra- or exta-hepatic biliary system or gallbladder.

Carcinoma of Intrahepatic and Extra-hepatic Biliary SystemCarcinoma of GallbladderBile Duct Cancer+1 more

Leap Therapeutics, Inc.51 participantsStarted Jun 2015

Los Angeles, California, United States • New Haven, Connecticut, United States • Boston, Massachusetts, United States +6 more locations

TERMINATED< 1 mile

A Long-term Follow-up Study of Patients Who Received VOR33

NCT05309733

VOR33 long-term follow-up (LTFU) study

Leukemia, Myeloid, Acute

Vor Biopharma10 participantsStarted Apr 2022

La Jolla, California, United States • Miami, Florida, United States • Bethesda, Maryland, United States +8 more locations

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

A Long-term Follow-up Study of Patients Who Received VOR33

Leukemia Trials in Other Cities

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Using Urine Samples to Identify Lung Cancer

Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission

Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer

Phase IB/II of CPX-351 for Relapse Prevention in AML

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

AE05ML Device for ML Hem-o-lok Polymer Clip Delivery in Laparoscopic Surgical Procedures Observational Registery Study

Open-Label Surufatinib in European Patients With NET

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

MGC018 With or Without MGA012 in Advanced Solid Tumors

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

Transorb™ Self-Gripping Resorbable Mesh in High-risk Subjects Undergoing Open Repair of Ventral Hernia

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Other Conditions in New York